📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Gland Pharma Appoints Dr. Jitendra Gangwal as VP of R&D to Lead Complex Product Development
Gland Pharma has appointed Dr. Jitendra Gangwal as Vice-President of Research and Development, effective February 18, 2026. Dr. Gangwal brings over 24 years of experience in pharmaceutical R&D, having previously held leadership roles at Dr. Reddy’s, Glenmark, and Alkem Laboratories. His track record includes the development of 55+ products and filing 10+ patents, specifically in complex delivery systems like liposomes and peptides. This strategic hire is intended to bolster Gland Pharma's pipeline of high-value complex injectables for regulated global markets.
Key Highlights
Dr. Jitendra Gangwal appointed as VP (R&D) with over 24 years of pharmaceutical experience.
Developed 55+ products across injections, ophthalmics, inhalation, and nasal routes.
Filed 10+ patents and led multiple 505(b)(2) and ANDA filings in previous roles.
Expertise in complex parenterals, nano-crystals, liposomes, and advanced polymer-based delivery systems.
💼 Action for Investors
Investors should view this as a positive move to strengthen the company's core R&D capabilities. Monitor the pace of new ANDA filings and complex product approvals over the next 12-18 months to gauge the impact of this leadership change.
Gland Pharma Gets USFDA Approval for Zoledronic Acid Injection; US Market Size $6.7 Million
Gland Pharma has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/100 mL) in single-dose bags. The product is indicated for treating Hypercalcemia of Malignancy, Multiple Myeloma, and Bone Metastases of Solid Tumors. According to IQVIA data, the product's US market sales were approximately USD 6.7 million for the twelve months ending November 2025. This approval strengthens Gland's sterile injectable portfolio in the key US market.
Key Highlights
Received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Single-Dose Bags
Product is bioequivalent and therapeutically equivalent to the reference listed drug by InfoRLife
Target indications include Hypercalcemia of Malignancy and Multiple Myeloma
US market sales for the product were approximately USD 6.7 million for the year ending November 2025
💼 Action for Investors
Investors should view this as a positive incremental addition to Gland's US portfolio, though the individual market size is modest. Monitor the company's ability to maintain its track record of USFDA approvals and market share gains in the generic injectables space.
Gland Pharma Q3 FY26 Revenue Up 22% to ₹1,695 Cr; Plans ₹2,000 Cr Capex Over 5 Years
Gland Pharma reported a strong Q3 FY26 with revenue growing 22% YoY to INR 16,954 million and adjusted EBITDA rising 25% to INR 4,490 million. The company announced a significant five-year capex plan of INR 2,000 crores focused on complex injectables, BFS, and ophthalmic lines. A major capacity expansion for cartridge fill and finish from 40 million to 140 million units is underway to target the GLP-1 and peptide markets. Management also noted a visible EBITDA turnaround at Cenexi and maintained a high R&D spend of 5.4% of revenue.
Key Highlights
Revenue grew 22% YoY to INR 16,954 million in Q3 FY26, with 9M FY26 revenue up 12%.
Adjusted EBITDA increased 25% YoY to INR 4,490 million, reflecting better operating leverage.
Announced INR 2,000 crore capex over the next 5 years for brownfield expansions and CDMO contracts.
Expanding cartridge fill and finish capacity by 250% from 40 million to 140 million units.
Filed 9 ANDAs and launched 9 new products in the U.S. market during the quarter.
💼 Action for Investors
Investors should monitor the execution of the ₹2,000 Cr capex plan and the ramp-up of the expanded cartridge capacity, which are critical for long-term value growth. The turnaround in Cenexi and strong EBITDA growth suggest improving operational efficiency and a positive outlook for the stock.
Gland Pharma Q3 FY26: Adj. PAT Surges 37% YoY to ₹2,797 Mn; Revenue Up 22%
Gland Pharma delivered a strong performance in Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 Mn. The company's Adjusted PAT saw a significant jump of 37% YoY to ₹2,797 Mn, supported by a recovery in margins. Adjusted EBITDA margins improved to 26% from 23% in the previous quarter, reflecting better operational efficiency. The core base business remains the primary driver, contributing ₹11,790 Mn to revenue with a healthy 28% PAT margin.
Key Highlights
Consolidated Revenue from operations grew 22% YoY and 14% QoQ to ₹16,954 Mn
Adjusted PAT increased 37% YoY to ₹2,797 Mn, with a sharp 52% sequential growth
Adjusted EBITDA margin expanded to 26% in Q3 FY26 from 23% in Q2 FY26
Base business revenue grew 16% YoY to ₹11,790 Mn with an Adjusted PAT of ₹3,274 Mn
R&D expenditure for the base business stood at ₹650 Mn, accounting for 5.5% of its revenue
💼 Action for Investors
The strong double-digit growth in both top-line and bottom-line suggests a robust recovery in the injectable segment. Investors should maintain a positive outlook given the margin expansion and steady performance of the core business.
Gland Pharma Q3 FY26: Revenue Up 22% YoY, Adj. PAT Surges 37% to ₹2,797 Mn
Gland Pharma reported a robust performance for Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 million. The growth was primarily driven by strong execution in the US and Europe, alongside the Cenexi business reaching breakeven. Adjusted PAT witnessed a significant 37% YoY increase to ₹2,797 million, while Adjusted EBITDA margins remained healthy at 26%. Management highlighted consistent execution and a ramp-up in CDMO contracts as key drivers for future momentum.
Key Highlights
Consolidated Revenue from operations increased 22% YoY to ₹16,954 million.
Adjusted PAT grew by 37% YoY to ₹2,797 million, with margins improving to 16%.
European market revenue surged 54% YoY to ₹4,071 million, while US revenue grew 19% to ₹8,685 million.
Adjusted EBITDA stood at ₹4,490 million, up 25% YoY, with a margin of 26%.
R&D investments increased to ₹650 million from ₹437 million in the previous year.
💼 Action for Investors
The results indicate a strong recovery in profitability and successful integration of the Cenexi acquisition. Investors may consider this a positive signal for long-term growth, especially with the US and European markets showing double-digit growth.
Gland Pharma Q3 Revenue Jumps 22.5% YoY to ₹16,954 Million; Profitability Improves
Gland Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 22.5% year-on-year to ₹16,953.63 million. Sequentially, revenue increased by 14% from ₹14,868.75 million in the previous quarter, indicating robust business momentum. Profit before tax for the quarter stood at ₹3,864.74 million, showing resilience despite a rise in employee benefit expenses and material costs. The company also confirmed the reappointment of Grant Thornton Bharat LLP as internal auditors for the upcoming financial year.
Key Highlights
Consolidated revenue from operations rose 22.5% YoY to ₹16,953.63 million in Q3 FY26.
Quarter-on-quarter revenue growth was robust at 14% compared to ₹14,868.75 million in Q2 FY26.
Total income for the nine-month period ended Dec 2025 reached ₹48,927.22 million versus ₹43,611.74 million YoY.
Profit before tax for the quarter was ₹3,864.74 million, maintaining healthy operational margins.
Grant Thornton Bharat LLP reappointed as Internal Auditors for the financial year 2026-27.
💼 Action for Investors
The strong double-digit growth in revenue both YoY and QoQ suggests a recovery in core markets and effective scale-up. Investors should maintain a positive outlook while monitoring the impact of rising operational costs on net margins.
Gland Pharma Receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma has received USFDA approval for its ANDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is a generic equivalent to Alcon's Pataday Once Daily Relief, 0.7%, used for treating ocular itching from allergic conjunctivitis. This approval marks a significant addition to Gland's ophthalmic portfolio in the United States. The company continues to leverage its B2B model to expand its global footprint across 60 countries.
Key Highlights
Approval received from USFDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).
Therapeutically equivalent to Alcon Laboratories' Pataday Once Daily Relief, 0.7%.
Targeted at the treatment of ocular itching associated with allergic conjunctivitis.
Strengthens Gland Pharma's position in the high-value US ophthalmic market.
💼 Action for Investors
This approval is a positive catalyst for long-term growth in the US market; investors should maintain a positive outlook on the stock. Keep an eye on the launch timeline and potential market share gains in the OTC segment.